RhoVac AB hires business development expert David Colpman as lead advisor to assist in identifying potentially interested parties in company’s assets
RhoVac AB ("RhoVac") announced today, March 20, 2018 that the company has signed a contract with Colpman Consulting Ltd, UK to strengthen the business development of the company in order to identify potentially interested parties.
In line with RhoVac's business model to license or sell all, or part of its operations, as soon as possible after clinical phase I/II studies have been completed, RhoVac is investing aggressively in business development by hiring David Colpman at Colpman Consulting Ltd. David Colpman has extensive experience in business development within Life Science, where he has held a number of senior positions in global pharmaceutical companies. Among other positions, he has been Head of Business Development and Senior Vice President of Business Development at Shire, which led to a series of strategic mergers, acquisitions, licensing and divestment programs. During that time, he also led the sale of a variety of brands to Almirall (approximately 210 M$), as well as identified and implemented Shire's acquisition of Transkaryotic Therapies Inc (1.6 B$). David Colpman has been Director at Colpman Consulting Ltd since 2014 and is a board member at, among others, Orexo AB and Forendo Pharma Ltd.
David Colpman has also worked for a number of companies in Scandinavia. For example, he was lead advisor in Alligators Bioscience AB's agreement with Janssen Biotech, Inc. (700 M$) and in Bristol-Myers Squibb's acquisition of Cormorant Pharmaceuticals AB (500 M$).
RhoVac is a biotech company that is developing an immunotherapeutic cancer vaccine. The goal of the drug candidate RV001 is to develop a cancer vaccine that prevents or limits the spread (metastasis) of cancer - not only in prostate cancer, but potentially in all metastatic cancers. Currently, treatment phase in a first-in-man clinical study has been completed in patients with diagnosed prostate cancer, and results from the study are expected to be reported in Q2 2018.
Comments from David Colpman
- RhoVac is an exciting company that works in a very dynamic environment – immuno-oncology. RhoVac differs from other companies in the field, in that the focus is on the metastases and not on the primary tumor. The company has great potential and I look forward to our collaboration!
Comments from RhoVac´s CEO, Anders Ljungqvist
-I am delighted that David has accepted to be lead advisor and assist our business development in identifying potentially interested parties in our assets. Based on David and his associate’s extensive experience, network and track record of closed deals, and our exciting results confirming that RV001 is safe and able to establish a significant vaccine-mediated immune response, we have established an excellent platform for reaching our set goals for the business model at RhoVac.
For more information, please contact:
Anders Ljungqvist – VD, RhoVac AB
Phone: +45 4083 2365
This is an English version of an original Swedish press release communicated by RhoVac AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that RhoVac AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 20 March 2018.
About RhoVac AB
RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac's first drug candidate has completed pre-clinical phase and clinical phase I / II study has started spring 2017. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on AktieTorget, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com